Page 3 - Structural Heart News Today

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

Medtronic (NYSE: MDT) today announced data from a head-to-head trial backing its Evolut TAVR system against the Edwards Sapien platform.

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

Debra Wendland, RN recipient of DAISY Nurse Leader Award from HaysMed.

The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned a

The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned a

The Evolut FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

Medtronic announced that the FDA approved its next-generation Evolut FX+ transcatheter aortic valve replacement (TAVR) system.